Resources

This week, imphatec Ltd. has announced the close of an oversubscribed £1.5M seed round led by SynBioVen, with further participation from angel investors. imphatec is a British synthetic biology pharmaceutical company developing the first customisable-dose subcutaneous implant platform to treat chronic conditions.

Medannex Ltd (Edinburgh) today announced the presentation of updated clinical data from Module 1 of the ongoing ATTAINMENT study of MDX-124 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid.

Q3 UK biotech financing; Budget calls; early-stage funding gap; faster clinical trials; connecting Government and industry; digital and AI skills webinar

UK biotech venture capital investment reached £270 million, up 44% from £187 million in Q3 2025, according to new figures from the BioIndustry Association (“BIA”).

Reproducibility starts where setpoints end: in the control strategy that defines how your process actually runs

Quell Therapeutics announced that QEL-005, its CD19 B-cell activated Phenotype-Locked™ engineered nTreg therapy, has advanced to the second planned dose cohort in the CHILL Phase 1/2 clinical study.

Industry leaders gathered at Discovery Park on 14 October for The Lab of the Future & Green Chemistry Innovation, an event exploring pharmaceutical AI, automation and green chemistry, with speakers urging the industry to unite to share learnings and knowledge.

The technology set to transform data in life sciences

NRG Therapeutics announced a positron emission tomography (PET) imaging trial (NRG5051-102) to assess the biodistribution of its lead clinical asset NRG5051 has started.

Brainomix, announced the publication of new data from the REVISE PPF multicenter observational study demonstrating the potential of quantitative CT.

The right time to consider transfer pricing and how early stage biotechs can take a more pragmatic approach

Chris Molloy on investment for BIA members; TIME’s Best Inventions; MHRA 2030 Strategy; Rare disease medicines review; Party conferences; TechBio; and BIA's AGM

PIR International recently partnered with CellCentric in appointing Paolo Pucci as Independent Non-Executive Director.

IMU Biosciences has announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data.

Microbiotica announces the first close of a £36 million ($48 million) Series C financing.

Recursion announced a $200 million underwritten offering of common stock with leading healthcare and institutional investors.

Graham Hewson has been appointed as Chief Business Officer of the Royal Veterinary College (RVC) and Chief Executive Officer of the London Bioscience Innovation Centre (LBIC).

OMass Therapeutics announced an oversubscribed $310 million (£230 million) Series C financing round.

Brainomix, today announced a new partnership with the Pulmonary Fibrosis Foundation (PFF) to bring the voices of patients and caregivers into exploring how AI-powered imaging could support the care of people living with pulmonary fibrosis (PF) and other fibrotic interstitial lung diseases (ILD).